Istituto Cardiocentro
Lugano, Canton Ticino, 6900, Switzerland
Location status: Recruiting
Location contact
Hervé Schlotterbeck, Medical Doctor
CONTACT
CONTACT
NCT Number: NCT07450456
This study will assess, on patients requesting a pharmacological premedication in the preoperative period, if virtual reality reality could reduce the request of pharmacological premedication while maintaining a good level of comfort for the patient. The aim of this study is to understand if virtual reality could reduce the need for pharmacological premedication and their associated secondary effects.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Lugano, Canton Ticino, 6900, Switzerland
Location status: Recruiting
Hervé Schlotterbeck, Medical Doctor
CONTACT
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The study intervention will take place on the day of surgery, in the ward, once patient's pre-operative preparation has been completed. The virtual reality device will be started according to the choices made by the patient (scenario and music) for a 20 min session. During that time, the patient will be left at rest and the interactions with the patient will be limited as much as possible.
Time frame: Up to the initiation of pre-oxygenation (same day)
Time frame: Prior to initiation of pre-oxygenation (intraoperative period, same day)
The Richmond Agitation-Sedation Scale (RASS) will be used to assess the level of agitation and sedation in study participants. RASS is a validated 10-point scale ranging from -5 (unarousable) to +4 (combative), with 0 representing alert and calm. Negative scores indicate increasing levels of sedation, while positive scores indicate increasing agitation.
Time frame: Immediately after arterial line insertion and prior to initiation of pre-oxygenation (same day)
In the operative room, Pa02 and PaC02 (both in mmHg) will be extracted from the first arterial blood gas after insertion of arterial line while the patient is not under oxygen
Time frame: At end of induction, after airway securement (same day)
External evaluation by the anesthetist team of preceived patient's comfort in theater with a 5 points Lickert scale (from 1 to 5) with 1 beeing the lowest perceived comfort
Time frame: From 4 hours after patient's extubation up to 72 hours after patient's extubation
At least 4 hours after the end of anesthesia and patient's extubation, a qualitative survey will be conducted on patient's experience in the preoperative period
Time frame: From the beginning of the intervention up to the end of the intervention (planned duration of the intervention: 20 minutes)
Proportion of patients who required the interruption of the VR intervention
Time frame: From 4 hours after patient's extubation up to 72 hours after patient's extubation
Evaluation of patient's satisfaction regarding the pre-operative period with a 5 points Lickert scale (from 1 to 5) with 1 beeing the lowest perceived level of satisfaction
Time frame: From the beginning of the VR intervention up to 15 minutes after the end of the VR intervention
Symptoms of cybersickness such as disorientation, dizziness, eye problems (fatigue, blurred vision, headache) will be monitored
Time frame: From administration of anxiolytic medication until initiation of pre-oxygenation (same day)
For patients requesting a premedication, secondary effects like cognitive impairment, sedation, respiratory depressions will be registered
Time frame: Time interval (in minutes) between completion of the VR intervention and administration of anxiolytic premedication, including rescue premedication if applicable.
After the study intervention, patient will be asked if he still wants to assume anxiolytic premedication. In case of positive answer, anxiolytic premedication will be given and time will be noted. In case of negative answer, no anxiolytic premedication will be given. In the following moments, in case of change in patient's anxiety level with a secondary request of anxiolytic premedication, "rescue" premedication will be given and timing will be noted.
Time frame: From immediately before VR session to operating room entry (same day)
Change in Visual Analogue Scale for anxiety (VASA) between 3 time points. VASA scale ranges from 0 to10 with 10 corresponding to the highest level of anxiety.
Time frame: From immediately before VR session to operating room entry (same day)
Change in APAIS scale between 3 time points. APAIS score is a validated score to evaluate anxiety in the preoperative context. It ranges from 6 to 30 with the highest score corresponding to a high level of anxiety.
Time frame: From immediately before VR session to operating room entry (same day)
Variation of blood pressure (systolic arterial pressure, diastolic arterial pressure, mean arterial pressure) between 3 time points.
Time frame: From immediately before VR session to operating room entry (same day)
Variation of oxygen saturation measured with finger pulsoxymeter between three time points.
Time frame: From immediately before VR session to operating room entry (same day)
Variation of heart rate measured between three time points.
Contact information is provided by the study sponsor or research team.
Ente Ospedaliero Cantonale, Bellinzona
Other
Effect of Virtual Reality Immersion on the Need of Pharmacological Premedication Before Cardiac Surgery
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07689461
Anxiety, Anxiety Disorders
Malatya, Turkey (Türkiye)
View Trial DetailsNCT07525388
Anxiety, Anxiety Disorders
Erzurum, Turkey (Türkiye)
View Trial DetailsNCT07055178
Anxiety, Anxiety Disorders
Winnipeg, Manitoba, Canada
View Trial DetailsNCT05472909
Anxiety, Anxiety Disorders
Madison, Wisconsin, United States
View Trial Details